RU2337096C2 - Способ получения стереоизомера гликопиррония r,r (или s,s)-конфигурации - Google Patents
Способ получения стереоизомера гликопиррония r,r (или s,s)-конфигурации Download PDFInfo
- Publication number
- RU2337096C2 RU2337096C2 RU2005122497/04A RU2005122497A RU2337096C2 RU 2337096 C2 RU2337096 C2 RU 2337096C2 RU 2005122497/04 A RU2005122497/04 A RU 2005122497/04A RU 2005122497 A RU2005122497 A RU 2005122497A RU 2337096 C2 RU2337096 C2 RU 2337096C2
- Authority
- RU
- Russia
- Prior art keywords
- diastereomers
- mixture
- solvent
- quaternization
- carried out
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 title description 4
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 17
- 229960002462 glycopyrronium bromide Drugs 0.000 claims abstract description 15
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical class [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 65
- 239000002904 solvent Substances 0.000 claims description 42
- 238000005956 quaternization reaction Methods 0.000 claims description 33
- 238000001953 recrystallisation Methods 0.000 claims description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000002425 crystallisation Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 230000008025 crystallization Effects 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- -1 e anol Chemical compound 0.000 claims description 9
- 150000003839 salts Chemical group 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000061 acid fraction Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 17
- 238000000926 separation method Methods 0.000 description 16
- 238000005809 transesterification reaction Methods 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 4
- 0 CI(*)(CCC1)CC[C@@]1OC([C@@](C1CCCC1)(C1=CCCC=C1)O)=O Chemical compound CI(*)(CCC1)CC[C@@]1OC([C@@](C1CCCC1)(C1=CCCC=C1)O)=O 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229940015042 glycopyrrolate Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940102396 methyl bromide Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 2
- FLVFPAIGVBQGET-YFKPBYRVSA-N (3s)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@H](O)C1 FLVFPAIGVBQGET-YFKPBYRVSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WFLUEQCOAQCQLP-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1CCCC1 WFLUEQCOAQCQLP-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- UMBAZWVOBDBJAP-BVXPGSOGSA-N C[C@@H]1C=CSC1[C@H](CO[C@@H]1C[N](C)(CC=C)CC1)C1CCCC1 Chemical compound C[C@@H]1C=CSC1[C@H](CO[C@@H]1C[N](C)(CC=C)CC1)C1CCCC1 UMBAZWVOBDBJAP-BVXPGSOGSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FGMUSNHTKNGVQD-AWEZNQCLSA-N methyl (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-AWEZNQCLSA-N 0.000 description 1
- FGMUSNHTKNGVQD-CQSZACIVSA-N methyl (2s)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@@](O)(C(=O)OC)C=2C=CC=CC=2)CCCC1 FGMUSNHTKNGVQD-CQSZACIVSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0189602A AT412088B (de) | 2002-12-18 | 2002-12-18 | Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere |
| ATA1896/2002 | 2002-12-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005122497A RU2005122497A (ru) | 2006-01-20 |
| RU2337096C2 true RU2337096C2 (ru) | 2008-10-27 |
Family
ID=31192804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005122497/04A RU2337096C2 (ru) | 2002-12-18 | 2003-12-18 | Способ получения стереоизомера гликопиррония r,r (или s,s)-конфигурации |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7569598B2 (enExample) |
| EP (1) | EP1572641B1 (enExample) |
| JP (1) | JP2007524565A (enExample) |
| CN (1) | CN100349867C (enExample) |
| AT (2) | AT412088B (enExample) |
| AU (1) | AU2003290075B2 (enExample) |
| CA (1) | CA2510280C (enExample) |
| DK (1) | DK1572641T3 (enExample) |
| ES (1) | ES2383799T3 (enExample) |
| NO (1) | NO330851B1 (enExample) |
| NZ (1) | NZ541098A (enExample) |
| PL (1) | PL214802B1 (enExample) |
| PT (1) | PT1572641E (enExample) |
| RU (1) | RU2337096C2 (enExample) |
| WO (1) | WO2004054971A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2614412C2 (ru) * | 2011-12-22 | 2017-03-28 | Сербиос-Фарма Са | Непрерывный способ алкилирования циклических третичных аминов |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504463D0 (en) | 2005-03-03 | 2005-04-13 | Arakis Ltd | Method of crystallisation and purification |
| US20120022127A1 (en) * | 2009-04-09 | 2012-01-26 | Thomas Allmendinger | Process for preparing pyrrolidinium salts |
| CA2802584C (en) * | 2010-06-14 | 2018-08-21 | Chiesi Farmaceutici S.P.A. | Crystal form of glycopyrronium chloride |
| CN103159659A (zh) * | 2011-12-19 | 2013-06-19 | 沈阳药科大学 | 一种毒蕈碱受体拮抗剂格隆溴铵的制备方法 |
| CN102627595A (zh) * | 2012-03-09 | 2012-08-08 | 徐奎 | 一种制备格隆溴铵的方法 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| WO2014134510A1 (en) | 2013-02-28 | 2014-09-04 | Dermira, Inc. | Glycopyrrolate salts |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN107304178B (zh) * | 2016-04-21 | 2020-03-27 | 辽宁药联制药有限公司 | 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法 |
| CN107345945B (zh) * | 2016-05-05 | 2019-12-17 | 辽宁药联制药有限公司 | 一种拆分格隆溴铵对映体及杂质检查的高效液相色谱方法 |
| CN113234003B (zh) * | 2021-04-23 | 2024-02-02 | 广东嘉博制药有限公司 | 一种格隆溴铵及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU745331B2 (en) * | 1996-11-11 | 2002-03-21 | Meda Pharma Gmbh & Co. Kg | Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments |
-
2002
- 2002-12-18 AT AT0189602A patent/AT412088B/de not_active IP Right Cessation
-
2003
- 2003-12-18 AU AU2003290075A patent/AU2003290075B2/en not_active Ceased
- 2003-12-18 CA CA2510280A patent/CA2510280C/en not_active Expired - Fee Related
- 2003-12-18 RU RU2005122497/04A patent/RU2337096C2/ru active
- 2003-12-18 DK DK03782435.6T patent/DK1572641T3/da active
- 2003-12-18 AT AT03782435T patent/ATE548348T1/de active
- 2003-12-18 WO PCT/EP2003/014432 patent/WO2004054971A1/de not_active Ceased
- 2003-12-18 ES ES03782435T patent/ES2383799T3/es not_active Expired - Lifetime
- 2003-12-18 CN CNB2003801098187A patent/CN100349867C/zh not_active Expired - Fee Related
- 2003-12-18 US US10/540,187 patent/US7569598B2/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ541098A patent/NZ541098A/en not_active IP Right Cessation
- 2003-12-18 EP EP03782435A patent/EP1572641B1/de not_active Expired - Lifetime
- 2003-12-18 JP JP2004560470A patent/JP2007524565A/ja active Pending
- 2003-12-18 PL PL377441A patent/PL214802B1/pl unknown
- 2003-12-18 PT PT03782435T patent/PT1572641E/pt unknown
-
2005
- 2005-07-15 NO NO20053473A patent/NO330851B1/no not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| WO 98/21183 (NOE CHRISTIAN R., MUTSCHLER ERNST) 22.05.1998. SU 1416056 (АЛКАЛОИДА ВЕДЬЕСЕТИ ДЬЯР) 07.08.1988. US 2956062 (ROBINS CO INC) 11.10.1960. I. DEMIAN ET ALL, J. LIQ. CHROMATOGR., 1990, VOL.13, №46, 779-787. ZHI WANG ET ALL, J. HIGH RESOL. CHROMATOGR., 1996, VOL.19, №12, 697-699. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2614412C2 (ru) * | 2011-12-22 | 2017-03-28 | Сербиос-Фарма Са | Непрерывный способ алкилирования циклических третичных аминов |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20053473L (no) | 2005-09-19 |
| CA2510280C (en) | 2011-09-27 |
| NO20053473D0 (no) | 2005-07-15 |
| AU2003290075A1 (en) | 2004-07-09 |
| NO330851B1 (no) | 2011-08-01 |
| AT412088B (de) | 2004-09-27 |
| CN1751022A (zh) | 2006-03-22 |
| CA2510280A1 (en) | 2004-07-01 |
| CN100349867C (zh) | 2007-11-21 |
| AU2003290075B2 (en) | 2009-01-29 |
| ES2383799T3 (es) | 2012-06-26 |
| PT1572641E (pt) | 2012-06-15 |
| NZ541098A (en) | 2008-08-29 |
| EP1572641B1 (de) | 2012-03-07 |
| JP2007524565A (ja) | 2007-08-30 |
| US7569598B2 (en) | 2009-08-04 |
| ATE548348T1 (de) | 2012-03-15 |
| PL214802B1 (pl) | 2013-09-30 |
| PL377441A1 (pl) | 2006-02-06 |
| WO2004054971A1 (de) | 2004-07-01 |
| ATA18962002A (de) | 2004-02-15 |
| EP1572641A1 (de) | 2005-09-14 |
| US20060167275A1 (en) | 2006-07-27 |
| RU2005122497A (ru) | 2006-01-20 |
| DK1572641T3 (da) | 2012-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2337096C2 (ru) | Способ получения стереоизомера гликопиррония r,r (или s,s)-конфигурации | |
| FI117438B (fi) | Menetelmä optisesti rikastetun bupivakaiinin valmistamiseksi | |
| RU2162085C2 (ru) | Способ получения энантиомерно чистых соединений имидазолила, энантиомерно чистая кислая аддитивная соль имидазолила и d- или l-пироглутаминовой кислоты, моногидрат гидрохлорида энантиомерно чистых соединений имидазолила | |
| HU207312B (en) | Process for resolving cys-3-amino-4-/2-/2-furyl/-et-1-yl/-1-/methoxy-carbonyl-methyl/-azetidin-2-one through it's malic acid | |
| JP2007524565A5 (enExample) | ||
| WO2010079504A2 (en) | Stable r(+)-lansoprazole amine salt and a process for preparing the same | |
| CA2363284C (fr) | Procede de synthese de derives n-(mercaptoacyl)-amino-acides a partir d'acides acryliques alpha-subtitues | |
| JP4184260B2 (ja) | （ｒ）−（−）−２−ヒドロキシ−２−（２−クロロフェニル）酢酸の分割方法 | |
| JPH0366686A (ja) | アゼチジン―２―オン誘導体の分割法 | |
| JP2002516896A (ja) | Ｒ−（−）−カルニチンの立体選択的合成のための化学的方法 | |
| US11091436B2 (en) | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | |
| MXPA01013145A (es) | Metodo para separar las bases diastereomericas de 2-( (dimetilamino) metil)-1-(3-metoxifenil)-ciclohexanol. | |
| KR101125123B1 (ko) | 높은 광학적 순도의 ｓ-(-)-암로디핀을 제조하는 방법 및 그 중간생성 화합물 | |
| JP2873609B2 (ja) | トレオ―２―ヒドロキシ―３―（２―アミノフェニルチオ）―３―（４―メトキシフェニル）プロピオン酸低級アルキルエステルの光学分割法 | |
| ES2354221T3 (es) | Método de resolución óptica de amlodipina. | |
| KR20010079913A (ko) | (-)-α-(디플루오로메틸)오르니틴-모노히드로클로라이드일수화물의 제조 방법 | |
| FR2527210A1 (fr) | Enantiomeres d'hexahydro-2,3,3a,4,5,6 1h-indolo(3,2,1-de) (naphtyridine-1,5), leur procede de separation et leur application en therapeutique | |
| JP3001975B2 (ja) | 結晶性チアガビン塩酸塩−水和物、その製造方法および用途 | |
| JP4067319B2 (ja) | 光学分割法及び光学活性化合物の製造法 | |
| JPH023628A (ja) | 光学活性１−メチル−３−フェニルプロピルアミンの製法 | |
| JPH023627A (ja) | 光学活性１−メチル−３−フェニルプロピルアミンの製造法 | |
| JPH0319231B2 (enExample) | ||
| JPH111453A (ja) | シス−２−フルオロシクロプロパン−１−カルボン酸の光学活性体の製造方法 | |
| JPH06271512A (ja) | 光学活性トランス−１，２−ジアミノ−４−シクロヘキセンの製造方法 | |
| CZ201533A3 (cs) | Způsob izolace směsi enantiomerů |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20081203 |